Literature DB >> 20373340

RNA-mediated neurodegeneration in repeat expansion disorders.

Peter K Todd1, Henry L Paulson.   

Abstract

Most neurodegenerative disorders are thought to result primarily from the accumulation of misfolded proteins, which interfere with protein homeostasis in neurons. For a subset of diseases, however, noncoding regions of RNAs assume a primary toxic gain-of-function, leading to degeneration in many tissues, including the nervous system. Here we review a series of proposed mechanisms by which noncoding repeat expansions give rise to nervous system degeneration and dysfunction. These mechanisms include transcriptional alterations and the generation of antisense transcripts, sequestration of mRNA-associated protein complexes that lead to aberrant mRNA splicing and processing, and alterations in cellular processes, including activation of abnormal signaling cascades and failure of protein quality control pathways. We place these potential mechanisms in the context of known RNA-mediated disorders, including the myotonic dystrophies and fragile X tremor ataxia syndrome, and discuss recent results suggesting that mRNA toxicity may also play a role in some presumably protein-mediated neurodegenerative disorders. Lastly, we comment on recent progress in therapeutic development for these RNA-dominant diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20373340      PMCID: PMC2852186          DOI: 10.1002/ana.21948

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  61 in total

Review 1.  Mechanisms of RNA-mediated disease.

Authors:  Jason R O'Rourke; Maurice S Swanson
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

2.  Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy.

Authors:  Susan A M Mulders; Walther J A A van den Broek; Thurman M Wheeler; Huib J E Croes; Petra van Kuik-Romeijn; Sjef J de Kimpe; Denis Furling; Gerard J Platenburg; Geneviève Gourdon; Charles A Thornton; Bé Wieringa; Derick G Wansink
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-10       Impact factor: 11.205

3.  Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA.

Authors:  Thurman M Wheeler; Krzysztof Sobczak; John D Lueck; Robert J Osborne; Xiaoyan Lin; Robert T Dirksen; Charles A Thornton
Journal:  Science       Date:  2009-07-17       Impact factor: 47.728

4.  Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy.

Authors:  Robert J Osborne; Xiaoyan Lin; Stephen Welle; Krzysztof Sobczak; Jason R O'Rourke; Maurice S Swanson; Charles A Thornton
Journal:  Hum Mol Genet       Date:  2009-02-17       Impact factor: 6.150

5.  Pentamidine reverses the splicing defects associated with myotonic dystrophy.

Authors:  M Bryan Warf; Masayuki Nakamori; Catherine M Matthys; Charles A Thornton; J Andrew Berglund
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-12       Impact factor: 11.205

6.  Rational and modular design of potent ligands targeting the RNA that causes myotonic dystrophy 2.

Authors:  Melissa M Lee; Alexei Pushechnikov; Matthew D Disney
Journal:  ACS Chem Biol       Date:  2009-05-15       Impact factor: 5.100

7.  A simple ligand that selectively targets CUG trinucleotide repeats and inhibits MBNL protein binding.

Authors:  Jonathan F Arambula; Sreenivasa Rao Ramisetty; Anne M Baranger; Steven C Zimmerman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-08       Impact factor: 11.205

8.  Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3.

Authors:  Alexei Pushechnikov; Melissa M Lee; Jessica L Childs-Disney; Krzysztof Sobczak; Jonathan M French; Charles A Thornton; Matthew D Disney
Journal:  J Am Chem Soc       Date:  2009-07-22       Impact factor: 15.419

9.  RNA gain-of-function in spinocerebellar ataxia type 8.

Authors:  Randy S Daughters; Daniel L Tuttle; Wangcai Gao; Yoshio Ikeda; Melinda L Moseley; Timothy J Ebner; Maurice S Swanson; Laura P W Ranum
Journal:  PLoS Genet       Date:  2009-08-14       Impact factor: 5.917

10.  Genetic and chemical modifiers of a CUG toxicity model in Drosophila.

Authors:  Amparo Garcia-Lopez; Lidon Monferrer; Irma Garcia-Alcover; Marta Vicente-Crespo; M Carmen Alvarez-Abril; Ruben D Artero
Journal:  PLoS One       Date:  2008-02-13       Impact factor: 3.240

View more
  110 in total

Review 1.  Neurodegeneration the RNA way.

Authors:  Abigail J Renoux; Peter K Todd
Journal:  Prog Neurobiol       Date:  2011-11-03       Impact factor: 11.685

Review 2.  Epigenetics in nucleotide repeat expansion disorders.

Authors:  Fang He; Peter K Todd
Journal:  Semin Neurol       Date:  2012-01-21       Impact factor: 3.420

Review 3.  Positive muscle phenomena--diagnosis, pathogenesis and associated disorders.

Authors:  Hans G Kortman; Jan H Veldink; Gea Drost
Journal:  Nat Rev Neurol       Date:  2012-01-24       Impact factor: 42.937

4.  Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.

Authors:  Mariely DeJesus-Hernandez; Ian R Mackenzie; Bradley F Boeve; Adam L Boxer; Matt Baker; Nicola J Rutherford; Alexandra M Nicholson; NiCole A Finch; Heather Flynn; Jennifer Adamson; Naomi Kouri; Aleksandra Wojtas; Pheth Sengdy; Ging-Yuek R Hsiung; Anna Karydas; William W Seeley; Keith A Josephs; Giovanni Coppola; Daniel H Geschwind; Zbigniew K Wszolek; Howard Feldman; David S Knopman; Ronald C Petersen; Bruce L Miller; Dennis W Dickson; Kevin B Boylan; Neill R Graff-Radford; Rosa Rademakers
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

5.  Ovarian histopathological and ubiquitin-immunophenotypic features in fragile X-associated primary ovarian insufficiency: a study of five cases and selected controls.

Authors:  Martin C Chang; John J DeCaro; Mei Zheng; Marla Gearing; Lisa Shubeck; Stephanie L Sherman; Corrine K Welt
Journal:  Histopathology       Date:  2011-10-18       Impact factor: 5.087

Review 6.  New pathologic mechanisms in nucleotide repeat expansion disorders.

Authors:  C M Rodriguez; P K Todd
Journal:  Neurobiol Dis       Date:  2019-06-21       Impact factor: 5.996

Review 7.  Clinical neurogenetics: autosomal dominant spinocerebellar ataxia.

Authors:  Vikram G Shakkottai; Brent L Fogel
Journal:  Neurol Clin       Date:  2013-07-30       Impact factor: 3.806

Review 8.  Targeting RNA in mammalian systems with small molecules.

Authors:  Anita Donlic; Amanda E Hargrove
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-05-03       Impact factor: 9.957

Review 9.  Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS/FTD diseases.

Authors:  Giulietta Riboldi; Chiara Zanetta; Michela Ranieri; Monica Nizzardo; Chiara Simone; Francesca Magri; Nereo Bresolin; Giacomo P Comi; Stefania Corti
Journal:  Mol Neurobiol       Date:  2014-05-09       Impact factor: 5.590

Review 10.  RNA Binding Proteins and the Pathogenesis of Frontotemporal Lobar Degeneration.

Authors:  Jeffrey W Hofmann; William W Seeley; Eric J Huang
Journal:  Annu Rev Pathol       Date:  2018-10-24       Impact factor: 23.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.